Literature DB >> 15136237

Xenobiotic gene polymorphisms and susceptibility to multiple myeloma.

Lisa F Lincz, Ian Kerridge, Fiona E Scorgie, Michael Bailey, Arno Enno, Andrew Spencer.   

Abstract

Genetic variations in the activity of xenobiotic enzymes may predict susceptibility to multiple myeloma (MM). In a case-control study, 90 Australian Caucasians with MM had significantly higher incidences of GST T1 null, PON1 BB and NAT2 slow acetylation genotypes, but no difference in polymorphism frequencies for GST M1, NAT1, and CYP1A1 when compared to 205 controls.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15136237

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  12 in total

Review 1.  Genetic predisposition for multiple myeloma.

Authors:  Maroulio Pertesi; Molly Went; Markus Hansson; Kari Hemminki; Richard S Houlston; Björn Nilsson
Journal:  Leukemia       Date:  2020-01-08       Impact factor: 11.528

2.  Paraoxonase 1 192 and 55 polymorphisms in osteosarcoma.

Authors:  Arzu Ergen; Onder Kılıcoglu; Harzem Ozger; Bedia Agachan; Turgay Isbir
Journal:  Mol Biol Rep       Date:  2010-11-23       Impact factor: 2.316

3.  Differential effects of paraoxonase 1 (PON1) polymorphisms on cancer risk: evidence from 25 published studies.

Authors:  Dai-Hua Fang; Cong-Hai Fan; Qiang Ji; Bo-Xiang Qi; Juan Li; Lu Wang
Journal:  Mol Biol Rep       Date:  2012-02-10       Impact factor: 2.316

4.  Association of NAT2 phenotype with risk of head and neck carcinoma: A meta-analysis.

Authors:  Youyang Zheng; Yong Li; Yaoshu Teng; Zhen Zhang; Xiaolin Cao
Journal:  Oncol Lett       Date:  2011-11-24       Impact factor: 2.967

5.  Genetic polymorphisms in the Paraoxonase 1 gene and risk of ovarian epithelial carcinoma.

Authors:  Galina Lurie; Lynne R Wilkens; Pamela J Thompson; Katharine E McDuffie; Michael E Carney; Keith Y Terada; Marc T Goodman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-08       Impact factor: 4.254

6.  N-acetyltransferase 1 and 2 gene sequence variants and risk of head and neck cancer.

Authors:  Semra Demokan; Yusufhan Suoglu; Mustafa Gözeler; Deniz Demir; Nejat Dalay
Journal:  Mol Biol Rep       Date:  2009-11-08       Impact factor: 2.316

7.  NAT1 polymorphisms and cancer risk: a systematic review and meta-analysis.

Authors:  Kunyi Zhang; Lijuan Gao; Yuqi Wu; Jianyi Chen; Chengguang Lin; Shaohua Liang; Jianxin Su; Jinming Ye; Xuyu He
Journal:  Int J Clin Exp Med       Date:  2015-06-15

8.  Associations of common variants in genes involved in metabolism and response to exogenous chemicals with risk of multiple myeloma.

Authors:  Laura S Gold; Anneclaire J De Roos; Elizabeth E Brown; Qing Lan; Kevin Milliken; Scott Davis; Stephen J Chanock; Yawei Zhang; Richard Severson; Sheila H Zahm; Tongzhang Zheng; Nat Rothman; Dalsu Baris
Journal:  Cancer Epidemiol       Date:  2009-09-06       Impact factor: 2.984

9.  Genetic variation in cell cycle and apoptosis related genes and multiple myeloma risk.

Authors:  H Dean Hosgood; Dalsu Baris; Yawei Zhang; Sonja I Berndt; Idan Menashe; Lindsay M Morton; Kyoung-Mu Lee; Meredith Yeager; Shelia H Zahm; Stephen Chanock; Tongzhang Zheng; Qing Lan
Journal:  Leuk Res       Date:  2009-04-11       Impact factor: 3.156

10.  Variations in suppressor molecule ctla-4 gene are related to susceptibility to multiple myeloma in a polish population.

Authors:  Lidia Karabon; Edyta Pawlak-Adamska; Anna Tomkiewicz; Anna Jedynak; Marek Kielbinski; Dariusz Woszczyk; Stanisław Potoczek; Anna Jonkisz; Kazimierz Kuliczkowski; Irena Frydecka
Journal:  Pathol Oncol Res       Date:  2011-07-09       Impact factor: 3.201
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.